VALERIO TX news, videos and press releases
For more news please use our advanced search feature.
VALERIO TX - More news...
VALERIO TX - More news...
- Valerio Therapeutics Announces Strategic Refocus
- Meeting of the Board of Directors of Valerio Therapeutics S.A. on November 13, 2024
- Half-Year Liquidity Contract Statement for Valerio Therapeutics
- Onxeo Changes Its Name and Becomes Valerio Therapeutics Following Approval by the Annual General Meeting of June 6, 2023
- Onxeo: Combined General Meeting of June 6, 2023: Availability of Preparatory Documents and Participation & Voting Procedures
- Onxeo: Publication of the 2022 Annual Financial Report
- Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates
- Onxeo will publish its full-year results on April 24, 2023
- Onxeo Will Publish Its Full-year Results on April 21, 2023
- Onxeo Will Publish Its Full-year Results on April 14, 2023
- Onxeo: Report on the Extraordinary General Meeting of February 6, 2023
- Onxeo Announces its Financial Agenda for 2023
- ONXEO Provides Update on the Development Program For Its First-in-class Drug Candidate AsiDNATM
- Onxeo: Extraordinary General Meeting of February 6, 2023: Availability of Preparatory Documents
- Half-year liquidity contract statement for ONXEO
- Onxeo Advances Its Second Lead Candidate OX425 for the Treatment of Solid Tumors
- Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities
- High-Grade Glioma Relapse in Children: Onxeo Announces the Enrollment of the First Patient in the Phase 1b/2 Clinical Study Conducted by the European ITCC Consortium and Sponsored by Institut Curie
- Onxeo Announces That Nasdaq Approved the Delisting of Its Shares From the First North Growth Market in Copenhagen
- Combined General Meeting of August 17, 2022: Onxeo Shareholders Approve Withdrawal From the Nasdaq First North Market in Copenhagen
- Onxeo S.A.: Combined General Meeting of August 17, 2022: Availability of Preparatory Documents and Participation & Voting Procedures
- Onxeo Announces a Combined General Meeting on August 17, 2022
- Summary of ONXEO’s Liquidity Contract with Kepler Cheuvreux
- Onxeo: Initial IND Application for AsiDNA Granted “Study May Proceed” by the U.S. FDA
- Onxeo: Proceedings of the Combined Shareholders’ Meeting of June 15, 2022
- Onxeo: Publication of the 2021 Annual Financial Report
- Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer
- Onxeo Reports its Full-Year 2021 Financial Results and Announces Additional Financing of €12 Million
- Onxeo to Present New Preclinical Data Highlighting AsiDNA™’s Ability to Fight Tumor Resistance and Protect From Anticancer Treatment Toxicity at AACR Annual Meeting 2022
- Onxeo’s New Preclinical Data Confirm the Relevance of Combining AsiDNA™ With PARP Inhibitors in Treating Homologous Recombination Proficient Tumors
